Figure 3.

Post hoc analysis of MPE. (A) Changes in pleural effusion 8 weeks after registration in this study. One patient refused the protocol treatment on day 29 and was excluded from the analysis. MPE in one patient was increased within 8 weeks after ramucirumab plus docetaxel without requiring drainage assessed by the investigator with chest radiography. One patient discontinued the protocol treatment on day 29 because of treatment refusal and was excluded from the analysis. (B) pePFS. pePFS was defined as the time from treatment to the evidence of grade 3 pleural effusion. MPE, malignant pleural effusion; pePFS, pleural effusion progression-free survival.